Physicians' Academy for Cardiovascular Education

Anticoagulation 2017: The key lessons and implications from recent clinical trials (2)

Jan. 12, 2018 - Prof. John Eikelboom, McMaster University, Hamilton, Ontario, Canada

HbA1c in CVD

Feb. 14, 2018 - Prof Naveed Sattar, MD - University of Glasgow, United Kingdom

Inflammation & CVD: Translating insights from vascular biology to the clinic

Nov. 16, 2017 - Prof. Peter Libby, USA

Diabetic patients with chronic kidney disease may benefit more from GLP-1 analogue treatment

Nov. 15, 2017

Anticoagulation 2017: The key lessons and implications from recent clinical trials (1)

Jan. 12, 2018 - Prof. John Eikelboom, McMaster University, Hamilton, Ontario, Canada

Natural history of DM: Focus on micro- and macrovascular complications

Feb. 13, 2018 - Prof. Kausik Ray, Imperial College Londen, UK

The new era of residual risk reduction

Nov. 16, 2017 - Prof. Erik Stroes - Amsterdam, The Netherlands

The patient with inflammatory residual risk: Who is it?

Nov. 16, 2017 - Prof. Wolfgang Koenig - Munich, Germany

Diabetic dyslipidemia and residual risk in the era of LDL control

Jan. 25, 2018 - Boston, MA, USA - Dr. Aruna Pradhan - Brigham & Women's Hospital, Boston, USA

Lipoprotein metabolism & CV risk: a long road from understanding to treatment

Jan. 6, 2017 - Prof. John JP Kastelein, Amsterdam, The Netherlands

Diabetes therapies and CVD – Does the ‘how’ matter more than the how much?

Oct. 27, 2017 - Boston, MA, USA - Dr. Stephen Wiviott - Brigham & Women's Hospital, Boston, USA

REVEALing where we stand with HDL

Oct. 26, 2017 - Boston, MA, USA - Dr. Christopher Cannon - Brigham & Women's Hospital, Boston, USA

Lipid management in primary prevention: Challenges in the era of low LDL-c & novel therapies

Oct. 26, 2017 - Boston, MA, USA - Dr. Samia Mora - Brigham & Women's Hospital, Boston, MA, USA

Integrating anti-PCSK9 therapy into primary and secondary prevention of CVD

Oct. 26, 2017 - Boston, MA, USA - Prof. Deepak Bhatt - Brigham & Women's Hospital, Boston, MA, USA

Can LDL go too low? Lessons from 25 years of cholesterol lowering

Oct. 26, 2017 - Boston, MA, USA - Dr. Robert Giugliano - Brigham & Women's Hospital, Boston, USA

There is hope for treatment of HFpEF

Nov. 24, 2017 - WCN congress, Amsterdam, The Netherlands - Prof. Carolyn Lam, MD - Singapore

Staggering results for weight reduction in T2DM

Dec. 18, 2017 - IDF 2017 - Abu Dhabi, UAE - Prof Naveed Sattar, MD - Glasgow, UK

New therapeutic options can make a difference for diabetic patients with high CV risk

Aug. 29, 2017 - Prof. John E Deanfield, MD - London, UK

Novel insights in the management and prognosis of pulmonary hypertension

Aug. 29, 2017 - ESC 2017, Barcelona, Spain - Prof Nazzareno Galiè - Bologna, Italy

Neurotoxin injection did not prevent the common complication of AF after cardiac surgery

Nov. 15, 2017 - AHA 2017 - Anaheim, CA, USA - Nathan Waldron, MD - Durham, NC, USA.

PCSK9 inhibition reduces atherogenic lipid levels in T2DM patients with mixed dyslipidemia

Feb. 22, 2018 - Ray KK, et al. - Diab Obes Metabol 2018

In type 2 diabetic patients with mixed dyslipidemia on maximal statin therapy, the addition of the PCSK9 inhibitor alirocumab is more effective than usual care.

Higher apolipoprotein A1 levels associated with lower risk of ischemic CV outcomes in atrial fibrillation

Feb. 21, 2018 - Pol T, et al. - J Am Heart Assoc. 2018

In patients with atrial fibrillation on oral anticoagulation, higher ApoA1 levels were associated with a lower risk of stroke, systemic embolism, and all-cause and CV mortality.

Diabetes increases mortality and morbidity risk in older ischemic stroke patients

Feb. 20, 2018 - Echouffo-Tcheugui JB, et al. - Eur Heart J 2018
In patients with ischemic stroke ≥ 65 years, diabetes is associated with a higher risk of mortality, recurrent events, HF and hospitalisations.

In patients with ischemic stroke ≥ 65 years, diabetes is associated with a higher risk of mortality, recurrent events, HF and hospitalisations.

Anticoagulation 2017: The key lessons and implications from recent clinical trials (2)

Latest frontiers in anticoagulation therapy (2/4)

Jan. 12, 2018 - Prof. John Eikelboom, McMaster University, Hamilton, Ontario, Canada
Prof. John Eikelboom summarizes results from COMPASS / Hokusai VTE Cancer trials and discusses the implications for clinical practice

Latest frontiers in anticoagulation therapy Prof. John Eikelboom summarizes results from COMPASS / Hokusai VTE Cancer trials and discusses the implications for clinical practice.

HbA1c in CVD

5 Things a cardiologist needs to know about diabetes

Feb. 14, 2018 - Prof Naveed Sattar, MD - University of Glasgow, United Kingdom
Prof Naveed Sattar discusses the value of HbA1c to diagnose T2DM, and how HbA1c levels are related to the risk of developing micro and macrovascular disease and the consequences thereof for choosing a HbA1c therapeutic target.

5 Things a cardiologist needs to know about diabetes Prof Naveed Sattar discusses the value of HbA1c to diagnose T2DM, and how HbA1c levels are related to the risk of developing micro and macrovascular disease and the consequences thereof for choosing a HbA1c therapeutic target.

Inflammation & CVD: Translating insights from vascular biology to the clinic

Nov. 16, 2017 - Prof. Peter Libby, USA
Prof. Libby explains the role of IL-1β in CV disease and the effects of antiinflammatory therapy targeting the IL-1β innate immunity pathway with canakinumab

Prof. Libby explains the role of IL-1β in CV disease and the effects of antiinflammatory therapy targeting the IL-1β innate immunity pathway with canakinumab

Diabetic patients with chronic kidney disease may benefit more from GLP-1 analogue treatment

Nov. 15, 2017
Prof. Neil Poulter gives an overview of a subgroup analysis of the LEADER trial in which patients with CKD treated with liraglutide showed a reduction of CV events as compared with those on placebo treatment.

Prof. Neil Poulter gives an overview of a subgroup analysis of the LEADER trial in which patients with CKD treated with liraglutide showed a reduction of CV events as compared with those on placebo treatment.

Suboptimal medical therapy for ACS patients is associated with increased mortality

Feb. 15, 2018 - Hoedemaker NPG et al. - Eur Heart J - CV Pharmacotherapy 2018

In a single-center observational study, less than 50% of acute coronary syndrome patients were on recommended therapies at discharge, which was associated with an increase in 1-year mortality.

Anticoagulation 2017: The key lessons and implications from recent clinical trials (1)

Latest frontiers in anticoagulation therapy (1/4)

Jan. 12, 2018 - Prof. John Eikelboom, McMaster University, Hamilton, Ontario, Canada
Prof. John Eikelboom summarizes results from RE-CIRCUIT / RE-DUAL PCI trials and discusses the implications for clinical practice

Latest frontiers in anticoagulation therapy Prof. John Eikelboom summarizes results from RE-CIRCUIT / RE-DUAL PCI trials and discusses the implications for clinical practice.

Increase of physical activity over time associated with lower HF risk

Feb. 14, 2018 - Florido R, et al. - Circulation 2018
In a community-based population without baseline CVD, increasing physical activity over 6 years was associated with reduced HF risk over the next two decades.

In a community-based population without baseline CVD, increasing physical activity over 6 years was associated with reduced HF risk over the next two decades.

Post-MI patients with multi-vessel disease may benefit from long-term P2Y12 inhibitor therapy

Feb. 14, 2018 - Bansilal S, et al. - J Am Coll Cardiol 2018
Patients with a history of MI and MVD are at increased risk for MACE and coronary events compared to those without MVD and benefit from long-term ticagrelor therapy.

Patients with a history of MI and MVD are at increased risk for MACE and coronary events compared to those without MVD and benefit from long-term ticagrelor therapy.

Catheter ablation improves mortality and morbidity in patients with heart failure and atrial fibrillation

Feb. 13, 2018 - Marrouche NF, et al. - N Engl J Med 2018
Catheter ablation is associated with a lower mortality and morbidity rate compared to  medical therapy in patients with heart failure and atrial fibrillation.

Catheter ablation is associated with a lower mortality and morbidity rate compared to medical therapy in patients with heart failure and atrial fibrillation.